by | Apr 28, 2024 | Publications
Lancet Haematol. 2024 Apr 24:S2352-3026(24)00097-8. doi: 10.1016/S2352-3026(24)00097-8. Online ahead of print. NO ABSTRACT PMID:38677301 | DOI:10.1016/S2352-3026(24)00097-8
by | Apr 28, 2024 | Publications
Lancet Haematol. 2024 Apr 24:S2352-3026(24)00070-X. doi: 10.1016/S2352-3026(24)00070-X. Online ahead of print. ABSTRACT BACKGROUND: Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of...
by | Apr 28, 2024 | Publications
Transplant Cell Ther. 2024 May;30(5):462-464. doi: 10.1016/j.jtct.2024.04.002. NO ABSTRACT PMID:38677789 | DOI:10.1016/j.jtct.2024.04.002
by | Apr 28, 2024 | Publications
BMC Cardiovasc Disord. 2024 Apr 27;24(1):230. doi: 10.1186/s12872-024-03895-y. ABSTRACT BACKGROUND: Unidentified heart failure occurs in patients with multiple myeloma when their heart was involved. CMR with late gadolinium enhancement (LGE) and T1 mapping can...
by | Apr 26, 2024 | Publications
Thromb Res. 2024 Apr 12;238:37-40. doi: 10.1016/j.thromres.2024.04.008. Online ahead of print. NO ABSTRACT PMID:38663044 | DOI:10.1016/j.thromres.2024.04.008
by | Apr 26, 2024 | Publications
Leuk Res. 2024 Feb 1;141:107451. doi: 10.1016/j.leukres.2024.107451. Online ahead of print. ABSTRACT BACKGROUND: Circular RNAs (circRNAs) are associated with development and progression of multiple myeloma (MM). However, the role and mechanism of circ_0005615 in MM...